Qi Wei, PhD, SVP and Head of Tech Ops brings nearly two decades of process development and GMP manufacturing experience in cell and gene therapies. He joins us from Geneception Therapeutics which he co-founded as an executive-in-residence at F-Prime Capital. He has held several leadership roles in cell therapy development and has contributed to the development of several pioneering CAR-T products including Kymriah® at Novartis, the first CAR-T to be approved in the U.S., and Tecartus™ at Kite/Gilead, in addition to advancing many CAR-T and TCR-T clinical candidates. Qi holds a PhD in biomedical engineering from Columbia University.